- €2.38bn
- €3.66bn
- €2.64bn
- 57
- 59
- 76
- 73
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 23.49 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | -21.29% | ||
| Dividend Yield (f) | 1.31% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.02 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 10.06 | ||
| Price to Sales | 0.9 | ||
| EV to EBITDA | 10.31 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 1.49% | ||
| Return on Equity | 3.95% | ||
| Operating Margin | 2.25% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | n/a | 2,621.18 | 3,764.92 | 3,250.52 | 2,635.16 | 2,801 | 2,991.33 | 0.18% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | +302.41 | -58.29 | -47.09 | -29.17 | +6.62 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Synlab AG is a Germany based clinical laboratory and medical diagnostic services provider. The Company is engaged in laboratory services for human and veterinary medicine, as well as environmental analysis.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- February 4th, 2019
- Public Since
- April 30th, 2021
- No. of Employees
- 27,047
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
XETRA- Shares in Issue
- 219,775,222
- Address
- Moosacher Strasse 88, MUENCHEN, 80809
- Web
- https://ag.synlab.com/
- Phone
- +49 893076020
- Contact
- Mark Reinhard
- Auditors
- Deloitte GmbH Wirtschaftsprufungsgesellschaft
Latest News for SYAB
Upcoming Events for SYAB
Q1 2024 Synlab AG Earnings Release
Q1 2024 Synlab AG Earnings Call
Synlab AG Annual Shareholders Meeting
Q2 2024 Synlab AG Earnings Release
Q2 2024 Synlab AG Earnings Call
Similar to SYAB
Doccheck AG
XETRA
M1 Kliniken AG
XETRA
FAQ
As of Today at 19:21 UTC, shares in Synlab AG are trading at €10.84. This share price information is delayed by 15 minutes.
Shares in Synlab AG last closed at €10.84 and the price had moved by +15.2% over the past 365 days. In terms of relative price strength the Synlab AG share price has outperformed the FTSE Global All Cap Index by +6.26% over the past year.
The overall consensus recommendation for Synlab AG is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Synlab AG does not currently pay a dividend.
Synlab AG does not currently pay a dividend.
Synlab AG does not currently pay a dividend.
To buy shares in Synlab AG you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €10.84, shares in Synlab AG had a market capitalisation of €2.38bn.
Here are the trading details for Synlab AG:
- Country of listing: Germany
- Exchange: GER
- Ticker Symbol: SYAB
Based on an overall assessment of its quality, value and momentum Synlab AG is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Synlab AG is €11.90. That is 9.78% above the last closing price of €10.84.
Analysts covering Synlab AG currently have a consensus Earnings Per Share (EPS) forecast of €0.45 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Synlab AG. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -3.26%.
As of the last closing price of €10.84, shares in Synlab AG were trading +4.16% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Synlab AG PE ratio based on its reported earnings over the past 12 months is 23.49. The shares last closed at €10.84.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Synlab AG's directors